Research Progress in Co-Delivery of Anti-multidrug Resistant Small RNA and Anti-tumor Drugs with Nanocarriers
- Author:
Man-Shu ZOU
1
Author Information
- Publication Type:Journal Article
- Keywords: Co-delivery; Multidrug resistance; Nanocarrier; Small RNA
- From: Chinese Pharmaceutical Journal 2018;53(19):1621-1626
- CountryChina
- Language:Chinese
- Abstract: The efficacy of antineoplastic drugs in cancer treatment is often hampered by drug resistance of tumor cells, which is usually caused by abnormal gene expression. The formation mechanism of multidrug resistance is very complex. Conventional drugs or gene therapy usually only aim at a specific drug target, so it is difficult to effectively control the complex signaling pathways of drug-resistant cells. The co-delivery of small RNA (siRNA ormiRNA) and anti-tumor drugs with nanocarriers can maximize the synergistic effect, and reverse the multidrug resistance of tumor cells by silencing some related proteins. This review summarizes the mechanisms and advantages of the combination therapies involving RNA and antineoplastic drugs, in vitro and in vivo evaluation, as well as the recent advances in the co-delivery nanocarriers for these agents.
